Clinical Trials on Infection, Human Immunodeficiency Virus in Belgium

Total 683 results

GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
Université Catholique de Louvain
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection

Belgium
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I

United States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (SONNET)

Infection, Human Immunodeficiency Virus

United States, Canada, Italy, Belgium, Romania
ViiV Healthcare
GlaxoSmithKline

No longer available

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Infection, Human Immunodeficiency Virus

Belgium, Russian Federation, Italy, South Africa, Argentina, Switzerland, Poland
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
GlaxoSmithKline

Completed

KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects (ASSERT)

HIV Infection | Infection, Human Immunodeficiency Virus I

Germany, Belgium, United Kingdom, Spain, Ireland, Italy, France, Austria, Denmark, Netherlands, Switzerland, Portugal, Latvia
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
ViiV Healthcare
GlaxoSmithKline

Completed

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
ViiV Healthcare

Completed

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
Universitaire Ziekenhuizen KU Leuven
Sciensano

Terminated

Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients (GAIN)

Human Immunodeficiency Virus

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
Hasselt University
Ziekenhuis Oost-Limburg

Completed

Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections (RUNtoBBV)

Hepatitis B | Human Immunodeficiency Virus | Hepatitis c

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Erasmus Medical Center

Completed

Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV (DAHHS-2)

Hepatitis C | Human Immunodeficiency Virus | Acute Hepatitis C

Netherlands, Belgium
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Cesa Projects International

Unknown

AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

Genital Human Papilloma Virus Infection

Belgium
Universiteit Antwerpen

Completed

Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples (HPV-VACPLUS)

Human Papilloma Virus Infection

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis

Human Papilloma Virus

Belgium
Universiteit Antwerpen
Research Foundation Flanders

Completed

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study) (AB-SOP)

Human Papilloma Virus Infection

Belgium
Universiteit Antwerpen

Completed

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (ABSOP-FollowUp)

Human Papilloma Virus Infection

Belgium
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
Universitair Ziekenhuis Brussel

Recruiting

Relinking Diagnosed But Untreated HCV Patients Back Into Care. (Relink)

Hepatitis C Virus Infection

Belgium
Erasme University Hospital
Roche Diagnostics; LHUB-ULB

Terminated

Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room

RSV Infection | Influenza Viral Infections

Belgium
Alios Biopharma Inc.

Terminated

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Hepatitis C

Belgium
Lieselot Houspie

Unknown

Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting

Influenza-like Illness | Influenzal Acute Respiratory Infection

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Sciensano
Institute of Tropical Medicine, Belgium; Université Libre de Bruxelles; Mensura...

Completed

Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV)

COVID-19 | Influenza, Human | SARS Virus | Espiratory Tract Infections

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Centre Hospitalier Universitaire Saint Pierre

Active, not recruiting

Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) (Papillon)

HIV Infections | HPV - Anogenital Human Papilloma Virus Infection

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
Hasselt University
University Ghent

Completed

HBV/HCV/HIV in Belgian Prisons

HIV Infections | Hepatitis B | Hepatitis C

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Italy, Belgium, France, Lithuania
Hasselt University
Jessa Hospital; Ziekenhuis Netwerk Antwerpen (ZNA); Ziekenhuis Oost-Limburg; Algemeen... and other collaborators

Recruiting

HCV Reinfection After DAA Therapy in PWID in Belgium (REINF_HCV)

Drug Use | Hepatitis C Virus Infection, Response to Therapy of

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Gilead Sciences

Completed

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

Germany, Belgium, United Kingdom, France

Clinical Trials on Infection, Human Immunodeficiency Virus in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations